Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22;14(6):595-605.
doi: 10.1016/j.jcin.2020.12.037.

Basics of Coronary Thermodilution

Alessandro Candreva  1 , Emanuele Gallinoro  2 , Marcel van 't Veer  3 , Jeroen Sonck  4 , Carlos Collet  1 , Giuseppe Di Gioia  4 , Monika Kodeboina  4 , Takuya Mizukami  5 , Sakura Nagumo  5 , Danielle Keulards  3 , Stephane Fournier  6 , Nico H J Pijls  3 , Bernard De Bruyne  7
Affiliations
Free article
Review

Basics of Coronary Thermodilution

Alessandro Candreva et al. JACC Cardiovasc Interv. .
Free article

Abstract

Coronary microvascular dysfunction is a highly prevalent condition in both obstructive and nonobstructive coronary artery disease. Intracoronary thermodilution is a promising technique to investigate coronary microvascular (dys)function in vivo and to assess its most important metric: microvascular resistance. Here, the authors provide a practical review of bolus and continuous thermodilution for the measurement of coronary flow and microvascular resistance. The authors describe the basic principles of indicator-dilution theory and of coronary thermodilution and detail the practicalities of their application in the catheterization laboratory. Finally, the authors discuss contemporary clinical applications of coronary thermodilution-based microvascular assessment in humans and future perspectives.

Keywords: bolus coronary thermodilution; continuous coronary thermodilution; coronary microvascular dysfunction; indicator-dilution theory.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Drs. Kodeboina, Fournier, Di Gioia, and Sonk are supported by a research grant from CardioPaTh. Dr. Di Gioia is supported by the STAR program of Compagnia di San Paolo. Dr. Collet has received institutional consultancy fees from HeartFlow and Philips Volcano. Dr. van ’t Veer has received speaker fees from Abbott. Dr. Pijls has received institutional research grants from Abbott and Hexacath; has received consultancy fees from Abbott, Opsens, and GE; and holds minor equity positions in Philips, ASML, and HeartFlow. Dr. De Bruyne has received institutional consulting fees from Abbott Vascular, Boston Scientific, Opsens, and Siemens; has received institutional grant support from Abbott Vascular, Boston Scientific, Biotronik, and Medtronic; and holds equity positions in Philips, Siemens, GE, Bayer, HeartFlow, Edwards Lifesciences, and Ceyliad. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

LinkOut - more resources